(SENS) Senseonics Holdings, Common - Overview
Stock: Implantable Glucose Sensor, Smart Transmitter, Mobile App
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 79.2% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.88 |
| Alpha | -82.99 |
| Character TTM | |
|---|---|
| Beta | 1.938 |
| Beta Downside | 1.683 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.89% |
| CAGR/Max DD | -0.35 |
Description: SENS Senseonics Holdings, Common December 28, 2025
Senseonics Holdings, Inc. (NYSE MKT:SENS) is a commercial-stage medical-technology firm that designs, manufactures, and markets implantable continuous glucose monitoring (CGM) systems-including the Eversense family (Eversense, Eversense XL, Eversense E3, and Eversense 365)-for diabetes management in the United States and abroad. The platform combines a sub-cutaneous sensor, a rechargeable smart transmitter, and a mobile app that delivers real-time glucose data to patients and their care teams.
Key recent metrics: 2023 total revenue reached ≈ $71 million, driven primarily by the launch of the Eversense 365 system, while cash and cash equivalents stood at ≈ $210 million at year-end, providing roughly 18 months of runway under current burn rates (~$12 million per quarter). The CGM market is expanding at a compound annual growth rate of ~12 % (2023-2028) due to rising diabetes prevalence (≈ 10.5 % of U.S. adults) and increasing payer reimbursement for long-term implantable sensors, which can command higher price points than trans-cutaneous competitors. A pending FDA supplemental application for a next-generation sensor with a 180-day wear life could further differentiate Senseonics from rivals such as Dexcom and Abbott.
For a deeper, data-driven view of SENS’s valuation dynamics, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -64.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA 25.69 > 1.0 |
| NWC/Revenue: 356.1% < 20% (prev 235.0%; Δ 121.1% < -1%) |
| CFO/TA -0.40 > 3% & CFO -55.4m > Net Income -64.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.0m) vs 12m ago 44.80% < -2% |
| Gross Margin: 41.60% > 18% (prev -0.10%; Δ 4171 % > 0.5%) |
| Asset Turnover: 26.20% > 50% (prev 23.05%; Δ 3.15% > 0%) |
| Interest Coverage Ratio: -8.33 > 6 (EBITDA TTM -55.5m / Interest Expense TTM 6.94m) |
Altman Z'' -15.00
| A: 0.79 (Total Current Assets 131.3m - Total Current Liabilities 21.1m) / Total Assets 139.9m |
| B: -7.12 (Retained Earnings -996.2m / Total Assets 139.9m) |
| C: -0.49 (EBIT TTM -57.8m / Avg Total Assets 118.1m) |
| D: -16.13 (Book Value of Equity -996.0m / Total Liabilities 61.8m) |
| Altman-Z'' Score: -38.26 = D |
Beneish M -3.27
| DSRI: 1.16 (Receivables 9.37m/5.82m, Revenue 30.9m/22.2m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.01 (AQ_t 0.00 / AQ_t-1 0.05) |
| SGI: 1.39 (Revenue 30.9m / 22.2m) |
| TATA: -0.07 (NI -64.7m - CFO -55.4m) / TA 139.9m) |
| Beneish M-Score: -3.27 (Cap -4..+1) = AA |
What is the price of SENS shares?
Over the past week, the price has changed by +10.90%, over one month by +11.36%, over three months by +27.01% and over the past year by -60.59%.
Is SENS a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the SENS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.9 | 135.3% |
| Analysts Target Price | 18.9 | 135.3% |
| ValueRay Target Price | 6.3 | -21.9% |
SENS Fundamental Data Overview February 03, 2026
P/S = 10.2223
P/B = 3.6381
Revenue TTM = 30.9m USD
EBIT TTM = -57.8m USD
EBITDA TTM = -55.5m USD
Long Term Debt = 35.3m USD (from longTermDebt, last quarter)
Short Term Debt = 479.0k USD (from shortTermDebt, last quarter)
Debt = 41.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.39m USD (from netDebt column, last quarter)
Enterprise Value = 229.4m USD (299.5m + Debt 41.2m - CCE 111.3m)
Interest Coverage Ratio = -8.33 (Ebit TTM -57.8m / Interest Expense TTM 6.94m)
EV/FCF = -4.08x (Enterprise Value 229.4m / FCF TTM -56.2m)
FCF Yield = -24.48% (FCF TTM -56.2m / Enterprise Value 229.4m)
FCF Margin = -181.5% (FCF TTM -56.2m / Revenue TTM 30.9m)
Net Margin = -209.2% (Net Income TTM -64.7m / Revenue TTM 30.9m)
Gross Margin = 41.60% ((Revenue TTM 30.9m - Cost of Revenue TTM 18.1m) / Revenue TTM)
Gross Margin QoQ = 42.84% (prev 47.62%)
Tobins Q-Ratio = 1.64 (Enterprise Value 229.4m / Total Assets 139.9m)
Interest Expense / Debt = 2.84% (Interest Expense 1.17m / Debt 41.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.7m (EBIT -57.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.23 (Total Current Assets 131.3m / Total Current Liabilities 21.1m)
Debt / Equity = 0.53 (Debt 41.2m / totalStockholderEquity, last quarter 78.2m)
Debt / EBITDA = -0.12 (negative EBITDA) (Net Debt 6.39m / EBITDA -55.5m)
Debt / FCF = -0.11 (negative FCF - burning cash) (Net Debt 6.39m / FCF TTM -56.2m)
Total Stockholder Equity = 47.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.81% (Net Income -64.7m / Total Assets 139.9m)
RoE = -135.2% (Net Income TTM -64.7m / Total Stockholder Equity 47.9m)
RoCE = -69.51% (EBIT -57.8m / Capital Employed (Equity 47.9m + L.T.Debt 35.3m))
RoIC = -51.91% (negative operating profit) (NOPAT -45.7m / Invested Capital 88.0m)
WACC = 11.75% (E(299.5m)/V(340.7m) * Re(13.06%) + D(41.2m)/V(340.7m) * Rd(2.84%) * (1-Tc(0.21)))
Discount Rate = 13.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 30.20%
Fair Price DCF = unknown (Cash Flow -56.2m)
EPS Correlation: -41.04 | EPS CAGR: 1.93% | SUE: 0.10 | # QB: 0
Revenue Correlation: 73.70 | Revenue CAGR: 20.62% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.57 | Chg30d=-0.037 | Revisions Net=-1 | Analysts=7
EPS next Year (2026-12-31): EPS=-2.38 | Chg30d=-0.143 | Revisions Net=-1 | Growth EPS=-52.2% | Growth Revenue=+70.5%